NASDAQ: VINC - Vincerx Pharma, Inc.

Rentabilité sur six mois: -73.68%
Secteur: Healthcare

Calendrier des promotions Vincerx Pharma, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc.

plus de détails
was founded in 2019 is based in Palo Alto, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2020-05-27
ISIN US92731L1061
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://vincerx.com
Цена ао 5.12
Changement de prix par jour: +5.49% (0.1839)
Changement de prix par semaine: -6.33% (0.2071)
Changement de prix par mois: -26.52% (0.264)
Changement de prix sur 3 mois: -71.68% (0.685)
Changement de prix sur six mois: -73.68% (0.737)
Changement de prix par an: -83.56% (1.18)
Evolution du prix sur 3 ans: -98.06% (10)
Evolution du prix sur 5 ans: +0% (0.194)
Evolution des prix sur 10 ans: +0% (0.194)
Evolution des prix depuis le début de l'année: -32.87% (0.289)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 1.75 8
P/E 0 0
EV/EBITDA -0.2216 0
Total: 3.5

Efficacité

Nom Signification Grade
ROA, % -220.44 0
ROE, % -357.84 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.06 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 94586.67 10
Rentabilité EPS, % 21575.26 10
Total: 8
Plus de détails

Établissements Volume Partager, %
Goldman Sachs Group Inc 1709656 7.98
Sage Rhino Capital LLC 1703413 7.95
Long Focus Capital Management, LLC 1098753 5.13
Bank of America Corporation 1082863 5.06
Rock Springs Capital Management, LP 891719 4.16
Vanguard Group Inc 513420 2.4
Kingdon Capital Management LLC 385000 1.8
Rubric Capital Management LP 354377 1.65
Point72 Asset Management, L.P. 344827 1.61
ExodusPoint Capital Management, LP 324119 1.51



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Ahmed M. Hamdy M.D. Co-Founder, Chairman & CEO 657.54k 1965 (60 années)
Dr. Raquel E. Izumi Ph.D. Co-Founder, President, COO, Secretary & Director 591.54k 1970 (55 années)
Mr. Alexander A. Seelenberger M.B.A. Chief Financial Officer 491.69k 1979 (46 années)
Mr. Tom C. Thomas J.D. Founder, General Counsel & Chief Legal Officer 444.14k 1960 (65 années)
Dr. John C. Byrd M.D. Founder & Chairman of Scientific Advisory Board N/A
Dr. Hans-Georg Lerchen Ph.D. Chief Scientific Officer N/A
Ms. Gabriela Jairala Vice President of Investor Relations & Corporate Communications and Chief of Staff N/A
Ms. Melissa Merrick SPHR Senior Director of People & Culture and Head of Human Resource N/A
Dr. Beatrix Stelte-Ludwig Ph.D. Executive Chief Development Officer N/A
Ms. Karen Quarford M.B.A. Vice President of Quality Operations & Compliance

Adresse: United States, Palo Alto. CA, 260 Sheridan Avenue - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://vincerx.com